This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rabbani, L. E. Articles by Giardina, E.-G. V. Search for Related Content PubMed PubMed Citation Articles by Rabbani, L. E. Articles by Giardina, E.-G. V.

Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women

^* Cardiology Division and Center for Women’s Health, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA

View larger version (20K): [in a new window]   Figure 1 The percent change after oral conjugated equine estrogen (CEE) or transdermal estrogen on plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and von Willebrand factor (vWF), compared with baseline. For oral CEE, the test result of the percent change (p value by analysis of variance [ANOVA]) was p = 0.08 for PAI-1, p < 0.004 for t-PA, and p = 0.03 for vWF. For transdermal estrogen, the test result of the percent change (p value by ANOVA) was not significant: p = 0.34 for PAI-1; p = 0.23 for t-PA; and p = 0.24 for vWF. Solid bars = PAI-1; hatched bars = t-PA; and open bars = vWF.